Leerink Partnrs Downgrades Compass Therapeutics (NASDAQ:CMPX) to Hold

Leerink Partnrs cut shares of Compass Therapeutics (NASDAQ:CMPX - Free Report) from a strong-buy rating to a hold rating in a research note released on Friday,Zacks.com reports.

Several other brokerages have also issued reports on CMPX. Leerink Partners lowered Compass Therapeutics from an "outperform" rating to a "market perform" rating and decreased their target price for the company from $5.00 to $4.00 in a research report on Friday. LADENBURG THALM/SH SH raised Compass Therapeutics from a "neutral" rating to a "buy" rating and set a $5.00 target price for the company in a research report on Monday, September 16th. Wedbush reaffirmed an "outperform" rating and set a $8.00 target price on shares of Compass Therapeutics in a research report on Wednesday, August 7th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $10.00 target price on shares of Compass Therapeutics in a research report on Monday, November 11th. Two analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. Based on data from MarketBeat, Compass Therapeutics currently has a consensus rating of "Moderate Buy" and a consensus price target of $6.75.

Compass Therapeutics Stock Down 13.2 %

NASDAQ CMPX traded down $0.21 on Friday, reaching $1.38. The company had a trading volume of 1,348,934 shares, compared to its average volume of 438,274. The stock has a market capitalization of $189.87 million, a P/E ratio of -3.73 and a beta of 0.92. The company's fifty day moving average is $1.75 and its 200 day moving average is $1.42. Compass Therapeutics has a 52-week low of $0.77 and a 52-week high of $2.34.

Compass Therapeutics (NASDAQ:CMPX - Get Free Report) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.08) EPS for the quarter, beating analysts' consensus estimates of ($0.11) by $0.03. On average, research analysts expect that Compass Therapeutics will post -0.42 EPS for the current year.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the stock. Bleakley Financial Group LLC bought a new stake in shares of Compass Therapeutics during the 1st quarter valued at about $80,000. Vanguard Group Inc. boosted its position in shares of Compass Therapeutics by 1.7% during the 1st quarter. Vanguard Group Inc. now owns 4,152,197 shares of the company's stock valued at $8,221,000 after acquiring an additional 71,008 shares during the last quarter. CM Management LLC raised its holdings in shares of Compass Therapeutics by 148.0% during the 1st quarter. CM Management LLC now owns 310,000 shares of the company's stock valued at $614,000 after buying an additional 185,000 shares in the last quarter. Opaleye Management Inc. purchased a new position in shares of Compass Therapeutics during the 1st quarter valued at about $6,277,000. Finally, Bank of New York Mellon Corp raised its holdings in shares of Compass Therapeutics by 12.4% during the 2nd quarter. Bank of New York Mellon Corp now owns 283,938 shares of the company's stock valued at $284,000 after buying an additional 31,433 shares in the last quarter. Institutional investors own 68.43% of the company's stock.

About Compass Therapeutics

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.